Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: Experience and recommendations;Introducción ambulatoria de apomorfina en infusión subcutanea continua en paeientes con enfermedad de Parkinson avanzada: Experiencia y recomendaciones

Neurologia

Volumn 22, Issue 3, 2007, Pages 133-137

  Castaño, Belén ^a   Mateo, D ^a   Gimenez Roldan S ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Apomorphine; Continuous subcutaneous infusion; Dyskinesias; Motor fluctuations; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; LEVODOPA;

ABDOMINAL ABSCESS; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; FOLLOW UP; HEMATOMA; HOSPITAL ADMISSION; HUMAN; MEDICAL RECORD; MOOD CHANGE; MOTOR PERFORMANCE; NEUROPSYCHIATRY; OUTPATIENT CARE; PARKINSON DISEASE; PSYCHOSIS; QUALITY OF LIFE; RATING SCALE; SOMNOLENCE; SUBCUTANEOUS NODULE;

AGED; AMBULATORY CARE; ANTIPARKINSON AGENTS; APOMORPHINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRANULOMA; HUMANS; INFUSIONS, PARENTERAL; LEVODOPA; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PARKINSON DISEASE; PROSPECTIVE STUDIES; SUBCUTANEOUS TISSUE; TELEPHONE;

EID: 34247538315     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gancher ST, Nutt JG. Diurnal responsiveness apomorphine. Neurology 1987;37:1250-3.
2. Frankel JP, Kempster PA, Lees AJ, Stern GM. Comparison of the motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:1004-7.
3. Varma TR, Fox SH, Eldridge PR, Littlechild P, Byrne P, Forster A, et al. Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine. J Neurol Neurosurg Psychiatry 2003;74:170-4.
4. Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-70.
5. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-41.
6. Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Rektor I, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002;17:188-91.
7. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-7.
8. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-6. Erratum in: Neurology 1992;42:1436.
9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
10. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol 1992;49:1131-4.
11. Hugues AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990;25:336:S18.
12. Fahn S, Elton RS, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. En: Fahn S, et al., editores. Recent development in Parkinson's disease. Vol 2. Florham Park, NJ: MacMillan, 1987; p. 153-64.
13. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
14. Kartzinel R, Hunt RD, Calne DB. Bromocriptine in Huntington chorea. Arch Neurol 1976;33:517-8.
15. Schwab RS, England AC. Projection technique for evaluation surgery in Parkinson's disease. En: Gilligham FJ, et al., editores. Third Symposium in Parkinson's Disease. Edinburgh: Livingston, 1969; p. 152-7.
16. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
17. Geldmacher DS, Whitehouse PJ. Evaluation of dementia. N Engl J Med 1996;335:330-6.
18. Beck AT, Ward CH, Mendelson M, Mock J, Erbangh J. An inventory for measuring depression. Arch Gen Psychiatr 1961;4:53-63.
19. Cummings JL, Mega M, Gray K, Rosemberg-Thomspson RN. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
20. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's Disease. Qual Life Res 1995;4:241-8.
21. Martínez-Martín P, Frades Payo B. Quality of life in Parkinson's disease: validation study of the PDQ-39 Spanish version. The Grupo Centro for Study of Movement Disorders. J Neurol 1998; 245(Suppl. 1):S34-8.
22. Colzi A, Turner K, Lees A. Continous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-6.
23. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;20:403-6.
24. Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PA. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1988;26:1260.
25. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
26. Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease. Rev Neurol (Paris) 1990;146:116-22.
27. Steiger MJ, Quinn NP, Marsden CD. The clinical use of apomorphine in Parkinson's disease. J Neurol 1992;239:389-93.
28. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating in Parkinson's disease. En: Narabayashi H, Nagtsu T, Yanagisawa Y, Mizuno Y, editores. Parkinson's disease: from basic research to treatment. Adv Neurol 1993;60:656-9.
29. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Adv Neurol 1993;60:656-9.
30. Stocchi F, Bramante L, Monge A, Viselli F, Baronti F, Stefano E, et al. Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol 1993;60:653-5.
31. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusion therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 1995;10:37-43.
32. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65:709-16.
33. Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv Neurol 1999;80:545-8.
34. Alegret M, Valldeoriola F, Marti M, Pilleri M, Junque C, Rumia J, et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov Disord 2004;19:1436-9.